Has vorasidenib-VORANIGO been included in medical insurance and reimbursement policies?

Vorasidenib (trade name: VORANIGO) is currently not on the market in China and is therefore not included in the national or local medical insurance catalogue. Domestic patients cannot obtain the drug directly through public hospitals or regular pharmacies, nor can they reimburse related expenses through medical insurance. This means that if patients need to use vorsidenib, they must rely on clinical trials, overseas drug purchase or special import channels, and they must bear all costs and related risks themselves.

In overseas markets, the original drug price of voxanib is relatively high. The specifications of the US version are 40 mg×30 tablets, and each box sells for about 38 RMB. In addition, some overseas countries have launched generic drugs, and the ingredients of the drugs are basically the same as the original drugs. For example, the generic drugs of the same specifications produced by Lucius Pharmaceuticals in Laos sell for more than 7,000 yuan per box. In contrast, the price of generic drugs is obviously low, but there is no formal introduction channel in China, so there are still restrictions on domestic patient access.

Since vorsidenib is not registered in China, even if the drug is obtained through legal import or clinical trials, its cost cannot be reimbursed through the medical insurance system. Imported drugs usually have to bear additional costs such as tariffs, transportation and cold chain management. In addition, the drugs themselves are expensive and impose a heavy financial burden on patients. Therefore, when using vorsidenib, it is necessary to fully evaluate the affordability and feasible payment methods, and at the same time ensure that the source of the drug is regular, safe and reliable.

If vorsidenib is approved for marketing in China, it is expected to enter the medical insurance reimbursement system through national drug negotiations, and its price and accessibility may improve. Patients and doctors should continue to pay attention to domestic registration progress, medical insurance policy developments and related assistance projects. At the current stage, rational use of clinical trials or legal overseas drug purchase channels, combined with the guidance of professional doctors, can provide treatment opportunities while ensuring safety and efficacy, while avoiding unnecessary legal and economic risks.

Reference materials:https://www.drugs.com/